Diligence memo · auto-generated · as of July 2, 2026
Native Cardio, Inc.
Native Cardio, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Native Cardio, Inc. operates in Biotechnology, based in NAPLES.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Native Cardio, Inc. has raised $3.1M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $2.5M on 2019-02-08.
Most recent recorded round closed around 2025-02-25.
Valuation (modeled)modeled
Provath models Native Cardio, Inc. at approximately $506K (range $108K–$1.1M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.11× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 18 months.
Last raise 16 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 3.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 35% of Biotechnology peers (4293 compared).
Modeled value ranks above 1% of those peers.
Closest niche peers: Carna Inc., NRX Pharmaceuticals, Inc., Vicora, Inc., MH3D, Inc., Oral Genome Corp..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.